bpc-157 pharmacokinetics oral bioavailability of bpc 157 Pharmacokinetics, distribution, metabolism, and excretion body-protective compound 157, a potential drug for treating various wounds, in rats and dogs Injection vs Oral Peptide: – What are the recommendations for

Researched applications In the published preclinical and clinical literature the effects of Cagrilintide are documented in the following areas: Obesity (stand-alone) , Phase 2 data (Lau 2021, 10.8 % at 4.5 mg) Obesity + Semaglutide (CagriSema) , Phase 3 REDEFINE 1 (25.3 %) T2DM + obesity , Phase 3 REDEFINE 2 Cardiovascular prevention , Phase 3 REDEFINE 3 (n ~ 7000) MASLD/MASH , exploratory in Phase 2 Type 2 diabetes (monotherapy) , preclinical data Prediabetes , exploratory plans Science & studies 4.1 Key publications Lau D.C.W., Erichsen L., Francisco A.M., et al

Neither peptide is FDA-approved for human therapeutic use

It is not FDA or Health Canada approved for any use

Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment